GILD vs. TAK: Gilead Sciences vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Gilead Sciences (GILD) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Gilead Sciences (GILD) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Gilead Sciences (GILD) has a non-negative beta of 0.36.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Takeda Pharmaceutical (TAK) reports 0.56%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Takeda Pharmaceutical (TAK) reports 0.87%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Gilead Sciences (GILD) at 2.39% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both companies show strong earnings momentum, but Gilead Sciences (GILD) at 1,684.21% is the standout with EPS growth above its industry range; Takeda Pharmaceutical (TAK) at 77.96% also sits in the top quartile.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and Takeda Pharmaceutical (TAK) at 953.28% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Gilead Sciences (GILD) reports 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Takeda Pharmaceutical (TAK) trades at 300.29 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile relative to book while Gilead Sciences (GILD) at 15.88 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics